Allos Therapeutics Inc.'s stock drop last week after Celgene Corp. disclosed its plan to buy out competitor Gloucester Pharmaceuticals Inc. seemed to signal investor nail-biting over the market chances for Allos' recently approved peripheral T-cell lymphoma drug Folotyn, due to fully launch in the first quarter of next year. (BioWorld Insight) Read More
